Salarius Pharma reports Q3 net loss $14.4M; seclidemstat trial paused on safety, FDA partial hold

Decoy Therapeutics Inc.

2022-Q3 EPS reported -$12.13

Q3 2022 net loss $14.4M ($6.41/diluted share) vs $3.7M ($2.09) in Q3 2021; includes $8.9M goodwill impairment.
Cash and equivalents $16.8M at Sep 30, 2022, down from $29.2M at Dec 31, 2021; cash runway into H2 2023.
Seclidemstat sarcoma trial on partial clinical hold after SUSAR; enrollment paused in both company and MD Anderson studies.
SP-3164 IND on track for H1 2023; favorable preclinical data presented at ASH abstract.
Nine-month net loss $25.2M ($12.13/share) vs $8.7M ($5.41) in prior period; operating cash burn $12.9M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Decoy Therapeutics Inc. reported three and nine months ended September 30, 2022 results: net income Net loss for the third quarter of 2022 was $14.4 million, or $6.41 per share, EPS $6.41 per share.

Period: three and nine months ended September 30, 2022
Net income: Net loss for the third quarter of 2022 was $14.4 million, or $6.41 per share
EPS: $6.41 per share
Result: reported results

Exact text from the filing

Salarius Pharmaceuticals, Inc. (the “Company”) reported financial results for the three and nine months ended September 30, 2022

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001615219-22-000147

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.